Health Care Select Sector SPDR ETF (XLV)
The Big 3: XLV, ARM, NKE
Don Kaufman (@Theotrade) sees two strong bearish opportunities and one "shot" to the upside on Wednesday's Big 3. He sees a likely pullback in the State Street Health Care Sector SPDR ETF (XLV) amidst Moderna's (MRNA) stellar rally.
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?
Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of 0.08% versus 0.09% for the Vanguard fund.
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotech ETF VanEck Biotech ETF focuses exclusively on 25 biotechnology stocks while State Street Health Care Select Sector SPDR ETF holds 60 diverse healthcare names State Street Health Care Select Sector SPDR ETF has demonstrated higher risk-adjusted growth and a smaller maximum drawdown over the last five years
Showstopper Healthcare Earnings Elevate Use Case for XLV
Wednesday, August 5th may have felt like an average Summer day, but it actually represented a compelling inflection point for the healthcare industry. This is because a few key healthcare giants reported their Q2 2026 results, showing that the industry still has plenty of gas left in the tank.
Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?
State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35% for State Street SPDR S&P Biotech ETF. State Street Health Care Select Sector SPDR ETF offers a higher trailing-12-month dividend yield of 1.6% while State Street SPDR S&P Biotech ETF pays 0.4%.
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the Invesco Nasdaq Biotechnology ETF (IBBQ). IBBQ has significantly outperformed on a one-year basis, but has also experienced a much more severe five-year maximum drawdown.
XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years
XLV vs. IHE: Which Healthcare ETF Is the Better Buy?
The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry, while XLV spreads its bets across the broader healthcare sector.
XLV vs IYH: Which Healthcare ETF Wins on Cost and Yield?
State Street Health Care Select Sector SPDR ETF maintains a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Both funds are heavily concentrated in the healthcare sector, but State Street Health Care Select Sector SPDR ETF offers a higher trailing dividend yield of 1.60% iShares U.S. Healthcare ETF provides broader market coverage with 100 holdings, while the State Street fund focuses on 60 companies within the S&P 500
XLV vs FHLC: Which Healthcare ETF Fits Your Portfolio?
The State Street Health Care Select Sector SPDR ETF manages $41.7 billion in assets under management (AUM), providing significantly higher liquidity than the Fidelity MSCI Health Care Index ETF Fidelity MSCI Health Care Index ETF tracks a broader universe of 365 holdings compared to the concentrated 60-stock portfolio of the State Street fund Both healthcare funds share an identical 0.08% expense ratio, making them some of the most cost-efficient options in the sector
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
XLV: Healthcare Sector On The Mend, But Probably Not For Long
The State Street Health Care Select Sector SPDR ETF might be a port in the storm for a while, but its best upside is likely behind it for this cycle. A year 2000-like cycle is hinting again. That's where XLV breaks even for a while, as tech melts down. But relative return is not a “win” to me. Any stock with a good chart is a potential trade for me. But as an investment, XLV and most of its component stocks are too richly valued.
Drug Pipeline Wins State Street Over on Healthcare
State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm's Q3 2026 sector outlook upgraded healthcare from neutral to positive.
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?
State Street Health Care Select Sector SPDR ETF offers a lower expense ratio and a higher dividend yield than Invesco Nasdaq Biotechnology ETF Invesco Nasdaq Biotechnology ETF provides concentrated exposure to the biotech industry but has experienced higher volatility and a deeper maximum drawdown State Street Health Care Select Sector SPDR ETF tracks a broader index of 60 healthcare stocks from the S&P 500 compared to the Invesco fund's 253 biotech holdings
Not Just Tech: Invest in Innovation With Healthcare
Traditionally speaking, folks that have looked to tap into innovation in the AI space have done so through tech exposure, particularly with mega-cap names. This is not a surprise, considering the interplay between these companies and AI innovation.
Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up
Ben Snider, Chief U.S. Equity Strategist at Goldman Sachs, went on CNBC to say something that should register with anyone who has been happily riding this market higher. The character of this market is shifting midyear, and the driver is a substantial increase in a substantial increase in leverage across investor types: retail margin debt,... Goldman's Top Strategist Sees a Dangerous Amount of Leverage Piling Up
Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?
If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the State Street Health Care Select Sector SPDR ETF ETF (XLV), a passively managed exchange traded fund launched on December 16, 1998.
The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026
The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year.
Health Care ETFs: XLV Delivers Low Fees and Solid Returns
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
3 Ridiculously Cheap Healthcare Stocks to Buy in June
Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of... 3 Ridiculously Cheap Healthcare Stocks to Buy in June